• Follow
  • Follow
  • Follow
  • About
    • About
    • Management Team
    • Board of Directors
  • Our Businesses
    • Active Ingredients (Ceapro)
    • Oral Thin Film (Nualtis)
  • Technologies
  • Investors and News
    • Press Releases
    • Events & Presentations
    • Investor Contacts
    • Stock Information
    • Financial Filings
      • SEC Filings
      • SEDAR
    • Governance
      • Corporate Governance
      • Board Committees
      • Board Diversity Matrix
      • Clawback Policy
      • Annual Reports
    • Email Alerts
  • Contact

Aeterna Zentaris Reports First Quarter 2023 Financial Results

by jtcir-auto | May 9, 2023 | Press Releases

– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial Actively seeking alternate development and commercialization partners for Macrilen® (macimorelin) in...

Aeterna Zentaris Reports First Quarter 2023 Financial Results

by jtcir-auto | May 9, 2023 | Press Releases

– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial Actively seeking alternate development and commercialization partners for Macrilen® (macimorelin) in...

Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

by jtcir-auto | Apr 5, 2023 | Press Releases

U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and commercialization efforts continue to move forward in European...

Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

by jtcir-auto | Apr 5, 2023 | Press Releases

U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and commercialization efforts continue to move forward in European...

Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

by jtcir-auto | Mar 23, 2023 | Press Releases

– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025- Executing strategy to streamline advancement of development programs, build upon growing body of data across pipeline, and progress towards go/no-go...
« Older Entries
Next Entries »

Recent Posts

  • COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
  • COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS ACQUIRES NUALTIS CORP.
  • COSCIENS Biopharma Inc. Reports Q2 2026 Results

Recent Comments

No comments to show.
Latest News:

Stock Info

TSX:

 

 

Sign Up For Alerts

Click Here and Stay Up To Date With Cosciens News and Events

 

Contact Us

© 2026 COSCIENS BIOPHARMA   All Rights Reserved   Terms and Conditions  Privacy Policy

  • Follow
  • Follow
  • Follow